pageId: red-queen-bio
verifiedAt: 2026-02-22
totalCitations: 16
verified: 10
broken: 5
unverifiable: 1
citations:
  - footnote: 1
    url: https://www.redqueen.bio
    linkText: Red Queen Bio Website — - Mission, thesis, approach
    claimContext: "|-----------|------------|----------| | **Focus Area** | AI-enabled biothreat countermeasures | Maps AI-enabled biothreats with frontier labs and pre-builds medical countermeasures[^1] | | **Founded** | 2025 (launched November 2025) | Spun out of HelixNano, a clinical-stage mRNA therapeutics company"
    fetchedAt: 2026-02-22T02:24:37.560Z
    httpStatus: 200
    pageTitle: Red Queen Bio
    contentSnippet: Red Queen Bio 0 Red Queen Bio Today, we are launching Red Queen Bio, an AI biosecurity company. The Red Queen hypothesis describes a species’ co-evolution with ever-evolving opponents. As AI capabilities advance, biological risks grow exponentially. Our mission is to scale biological defenses at the same rate to ensure continuous human flourishing. We, the founders of Red Queen Bio (Nikolai and Hannu) have worked together for almost a decade as co-founders of HelixNano, a clinical-stage mRNA com
    contentLength: 84054
    status: verified
    note: null
  - footnote: 2
    url: https://techinformed.com/openai-leads-15-million-seed-in-red-queen-bio-for-ai-biosecurity/
    linkText: TechInformed - OpenAI leads \$15M seed in Red Queen Bio — - Funding announcement and context
    claimContext: "| **Focus Area** | AI-enabled biothreat countermeasures | Maps AI-enabled biothreats with frontier labs and pre-builds medical countermeasures[^1] | | **Founded** | 2025 (launched November 2025) | Spun out of HelixNano, a clinical-stage mRNA therapeutics company[^2] | | **Structure** | Public Benefi"
    fetchedAt: 2026-02-22T02:24:38.800Z
    httpStatus: 200
    pageTitle: OpenAI leads $15 million seed in Red Queen Bio for AI biosecurity - TechInformed
    contentSnippet: "OpenAI leads $15 million seed in Red Queen Bio for AI biosecurity - TechInformed Advertisement Breaking News November 14, 2025 OpenAI leads $15 million seed in Red Queen Bio for AI biosecurity Aman Gupta November 14, 2025 1 Minutes Read --> Red Queen Bio announced it raised a $15 million seed round led by OpenAI, launching an AI biosecurity company that aims to “scale biological defenses” as AI capabilities advance. The founders wrote that the company was spun out of HelixNano and that the seed "
    contentLength: 122036
    status: verified
    note: null
  - footnote: 3
    url: https://longevc.com/insights/tpost/f97x5o9ac1-longevc-portfolio-company-red-queen-bio
    linkText: LongeVC - Red Queen Bio Raises \$15M — - Investor details
    claimContext: '| **Structure** | Public Benefit Corporation (PBC) | Governance ensures mission precedence over individual partnerships[^1] | | **Funding** | \$15M seed round led by <EntityLink id="openai">OpenAI</EntityLink> | Additional investors: Cerberus Ventures, Fifty Years, Halcyon Futures, Dhuna Ventures, L'
    fetchedAt: 2026-02-22T02:24:38.311Z
    httpStatus: 200
    pageTitle: LongeVC Portfolio Company Red Queen Bio Raises $15M to Strengthen AI-Driven Biosecurity
    contentSnippet: LongeVC Portfolio Company Red Queen Bio Raises $15M to Strengthen AI-Driven Biosecurity Blog 2025-11-17 11:53 LongeVC Portfolio Company Red Queen Bio Raises $15M to Strengthen AI-Driven Biosecurity As AI systems accelerate both biological discovery and potential misuse, the core challenge is no longer identifying risks, but keeping pace with how quickly those risks can evolve. That requires defensive platforms that merge computational models with experimental validation and continuous threat map
    contentLength: 39188
    status: verified
    note: null
  - footnote: 4
    url: https://pitchbook.com/profiles/company/1162046-98
    linkText: PitchBook - Red Queen Bio Profile — - Company details
    claimContext: '| **Core Thesis** | "Defensive co-scaling" | Scale biological defenses proportionally with advancing AI capabilities[^1] | | **Headquarters** | Boston, MA | Co-located with HelixNano operations[^4] |'
    fetchedAt: 2026-02-22T02:24:37.400Z
    httpStatus: 200
    pageTitle: "Red Queen Bio 2026 Company Profile: Valuation, Funding & Investors | PitchBook"
    contentSnippet: "Red Queen Bio 2026 Company Profile: Valuation, Funding & Investors | PitchBook Red Queen Bio This is a profile preview from the PitchBook Platform. Request a free trial Red Queen Bio Overview Update this profile Year Founded 2025 Status Private Latest Deal Type Seed Latest Deal Amount $15M Investors 8 Red Queen Bio General Information Description Developer of biosecurity technology designed to defend against emerging biological threats enabled by artificial intelligence proactively. The company "
    contentLength: 231232
    status: verified
    note: null
  - footnote: 5
    url: https://en.wikipedia.org/wiki/Red_Queen_hypothesis
    linkText: Red Queen hypothesis - Wikipedia — - Name origin
    claimContext: "The company's core thesis is **defensive co-scaling for biology**: rather than merely using AI for biodefense, Red Queen Bio aims to couple \"defensive compute and funding to the same technological and financial forces that drive the capability race.\"[^1] The name derives from the **Red Queen hypothe"
    fetchedAt: 2026-02-22T02:24:36.927Z
    httpStatus: 403
    pageTitle: null
    contentSnippet: null
    contentLength: 0
    status: broken
    note: HTTP 403
  - footnote: 6
    url: https://www.helixnano.com/
    linkText: HelixNano Website — - Company history
    claimContext: HelixNano was founded in 2013 by Hannu Rajaniemi and Nikolai Eroshenko to develop next-generation mRNA technologies, initially focused on cancer vaccines.[^6] The company pivoted to COVID-19 vaccine development in March 2020 and advanced to clinical-stage mRNA therapeutics.[^7]
    fetchedAt: 2026-02-22T02:24:40.416Z
    httpStatus: 200
    pageTitle: HelixNano
    contentSnippet: HelixNano 0 What if a drug could design itself? What if it got better with every patient? What if you only ever needed one? More soon.
    contentLength: 391010
    status: verified
    note: null
  - footnote: 7
    url: http://www.startuplessonslearned.com/2020/06/out-of-crisis-10-helix-nano-founder.html
    linkText: Lean Startup - HelixNano founder interview — - COVID pivot and mRNA technology
    claimContext: HelixNano was founded in 2013 by Hannu Rajaniemi and Nikolai Eroshenko to develop next-generation mRNA technologies, initially focused on cancer vaccines.[^6] The company pivoted to COVID-19 vaccine development in March 2020 and advanced to clinical-stage mRNA therapeutics.[^7]
    fetchedAt: 2026-02-22T02:24:40.878Z
    httpStatus: 0
    pageTitle: null
    contentSnippet: null
    contentLength: 0
    status: broken
    note: fetch failed
  - footnote: 8
    url: https://www.investing.com/news/company-news/openai-invests-in-red-queen-bio-to-counter-aipowered-bioweapons-93CH-4356083
    linkText: Investing.com - OpenAI invests in Red Queen Bio — - Business model details
    claimContext: 2. Defensive biological infrastructure (countermeasures, surveillance, response) lags behind 3. The business model for biosecurity needed innovation -- borrowing from frameworks like catastrophic risk insurance[^8] 4. Defensive capabilities needed to be structurally linked to the same scaling dynami
    fetchedAt: 2026-02-22T02:24:40.235Z
    httpStatus: 200
    pageTitle: OpenAI invests in Red Queen Bio to counter AI-powered bioweapons By Investing.com
    contentSnippet: OpenAI invests in Red Queen Bio to counter AI-powered bioweapons By Investing.com Please try another search Popular News More Trump to raise global tariff rate to 15% after Supreme Court ruling 10% market drop could meaningfully dent U.S. consumption, BCA says BCA flags rising risk of Trump trade escalation by 2027 Is now time to double down on diversification? Get 50% Off Sign In Free Sign Up English (UK) English (India) English (Canada) English (Australia) English (South Africa) English (Phili
    contentLength: 963981
    status: verified
    note: null
  - footnote: 9
    url: https://x.com/jasonkwon/status/1989134714905481572
    linkText: Jason Kwon on X — - Defensive co-scaling endorsement
    claimContext: The concept of **defensive co-scaling** represents Red Queen Bio's central strategic framework. OpenAI Chief Strategy Officer Jason Kwon described it as "scaling the defensive capabilities of complementary technologies by linking them to the scaling of AI."[^9]
    fetchedAt: 2026-02-22T02:24:39.805Z
    httpStatus: null
    pageTitle: null
    contentSnippet: null
    contentLength: null
    status: unverifiable
    note: Social media domain — cannot verify automatically
  - footnote: 10
    url: https://www.dagens.com/technology/openai-funds-new-biotech-startup-to-counter-ai-enabled-bio-threats
    linkText: Dagens - OpenAI funds biotech startup — - Pipeline expansion plans
    claimContext: The company is expanding into an integrated AI-wet lab pipeline aimed at detecting vulnerabilities earlier, validating them experimentally, and strengthening the broader biodefense ecosystem.[^10]
    fetchedAt: 2026-02-22T02:24:40.904Z
    httpStatus: 200
    pageTitle: OpenAI funds new biotech startup to counter AI-enabled bio threats
    contentSnippet: "OpenAI funds new biotech startup to counter AI-enabled bio threats Homepage Technology OpenAI funds new biotech startup to counter AI-enabled bio threats OpenAI funds new biotech startup to counter AI-enabled bio threats Asger Risom • Photo Agency / Shutterstock.com OpenAI is expanding its efforts to contain emerging risks posed by artificial intelligence, backing a new biotech spinoff aimed at stopping malicious actors from using advanced models to create biological weapons. Others are reading "
    contentLength: 97891
    status: verified
    note: null
  - footnote: 11
    url: https://www.pharmiweb.com/press-release/2026-01-08/abtherx-and-red-queen-bio-partner-on-therapeutic-antibody-discovery
    linkText: PharmiWeb - AbTherx and Red Queen Bio Partnership — - January 2026 partnership announcement
    claimContext: On January 8, 2026, Red Queen Bio announced a therapeutic antibody discovery partnership with AbTherx, combining AbTherx's Atlas Full Human Diversity Transgenic Mouse platform with Red Queen Bio's vaccination and AI-driven antibody development pipeline.[^11]
    fetchedAt: 2026-02-22T02:24:42.751Z
    httpStatus: 200
    pageTitle: AbTherx and Red Queen Bio Partner on Therapeutic Antibody Discovery - PharmiWeb.com
    contentSnippet: "AbTherx and Red Queen Bio Partner on Therapeutic Antibody Discovery - PharmiWeb.com Search jobs 08-Jan-2026 AbTherx and Red Queen Bio Partner on Therapeutic Antibody Discovery Partnership has already generated high-quality, AI-ready data in less than three months MOUNTAIN VIEW, CA / ACCESS Newswire / January 8, 2026 / AbTherx today announced a therapeutic antibody discovery and development partnership with Red Queen Bio, combining AbTherx's Atlas ™ Full Human Diversity Transgenic Mouse platform "
    contentLength: 39687
    status: verified
    note: null
  - footnote: 12
    url: https://ca.finance.yahoo.com/news/openai-backs-startup-aiming-block-160408034.html
    linkText: Yahoo Finance - OpenAI backs startup — - Investment governance details
    claimContext: The OpenAI investment is notable for several reasons. It represents a direct financial commitment by a frontier AI lab to building defensive biological infrastructure against risks that its own technology could create. Jason Kwon and other OpenAI executives with prior exposure to the founders throug
    fetchedAt: 2026-02-22T02:24:42.835Z
    httpStatus: 0
    pageTitle: null
    contentSnippet: null
    contentLength: 0
    status: broken
    note: fetch failed
  - footnote: 13
    url: https://www.goodwinlaw.com/en/news-and-events/news/2025/12/announcements-lifesciences-goodwin-advises-red-queen-bio
    linkText: Goodwin - Red Queen Bio Seed Financing — - Legal counsel announcement
    claimContext: Legal counsel for the round was provided by Goodwin Procter LLP.[^13]
    fetchedAt: 2026-02-22T02:24:42.543Z
    httpStatus: 200
    pageTitle: Goodwin Advises Red Queen Bio on its $15 Million Seed Financing Led by OpenAI | News & Events | Goodwin
    contentSnippet: Goodwin Advises Red Queen Bio on its $15 Million Seed Financing Led by OpenAI | News & Events | Goodwin Press Release December 22, 2025 Goodwin Advises Red Queen Bio on its $15 Million Seed Financing Led by OpenAI Professionals Shoaib Ghias Sam Zucker Shane Albright Daniel S. Karelitz Bartek Sudol Candace Hagey View PDF Share The Life Sciences team advised Red Queen Bio in connection with its spin out from HelixNano and $15 million seed financing round led by OpenAI. Red Queen Bio, a biosecurity
    contentLength: 114652
    status: verified
    note: null
  - footnote: 14
    url: https://www.crunchbase.com/person/nikolai-eroshenko
    linkText: Nikolai Eroshenko - Crunchbase — - Education and background
    claimContext: Nikolai Eroshenko studied biomedical engineering at Virginia Commonwealth University (2005-2008) and earned his PhD in bioengineering from Harvard University (2008-2014), where he worked in George Church's lab on novel DNA synthesis technologies and genome engineering tools beyond CRISPR.[^14] He co
    fetchedAt: 2026-02-22T02:24:42.345Z
    httpStatus: 403
    pageTitle: null
    contentSnippet: null
    contentLength: 0
    status: broken
    note: HTTP 403
  - footnote: 15
    url: https://en.wikipedia.org/wiki/Hannu_Rajaniemi
    linkText: Hannu Rajaniemi - Wikipedia — - Biography
    claimContext: Hannu Rajaniemi (born March 9, 1978, in Ylivieska, Finland) is a Finnish-American scientist, entrepreneur, and science fiction author.[^15] He holds a PhD in Mathematical Physics from the University of Edinburgh, a Certificate of Advanced Study in Mathematics from Cambridge, and a BSc in Mathematics
    fetchedAt: 2026-02-22T02:24:41.920Z
    httpStatus: 403
    pageTitle: null
    contentSnippet: null
    contentLength: 0
    status: broken
    note: HTTP 403
  - footnote: 16
    url: https://techcrunch.com/2023/03/23/plural-vc-lures-mrna-vaccine-and-ai-pioneer-to-become-its-newest-partner/
    linkText: TechCrunch - Plural VC recruits Rajaniemi — - VC role
    claimContext: "Rajaniemi is known in literary circles for the Jean le Flambeur trilogy, beginning with *The Quantum Thief* (2010), which was nominated for the 2011 Locus Award for Best First Novel.[^15] He founded ThinkTank Maths, a commercial research organization, and co-founded HelixNano in 2013.[^15] In 2023, "
    fetchedAt: 2026-02-22T02:24:44.763Z
    httpStatus: 200
    pageTitle: Plural lures mRNA vaccine and AI pioneer to become its newest partner | TechCrunch
    contentSnippet: "Plural lures mRNA vaccine and AI pioneer to become its newest partner | TechCrunch &#8211;:&#8211;:&#8211;:&#8211; Save up to $680 on your pass with Super Early Bird rates. REGISTER NOW . Save up to $680 on your Disrupt 2026 pass. Ends February 27. REGISTER NOW . Close Image Credits: courtesy of Carina Namih Venture Plural lures mRNA vaccine and AI pioneer to become its newest partner Mike Butcher 6:50 AM PDT · March 23, 2023 Some say the European tech startup ecosystem lacks investors who have "
    contentLength: 232288
    status: verified
    note: null
